unbounded vegf165 Search Results


human vegf duoset elisa kit  (R&D Systems)
97
R&D Systems human vegf duoset elisa kit
Human Vegf Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf duoset elisa kit/product/R&D Systems
Average 97 stars, based on 1 article reviews
human vegf duoset elisa kit - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
unbounded vegf165  (Sino Biological)
93
Sino Biological unbounded vegf165
Unbounded Vegf165, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/unbounded vegf165/product/Sino Biological
Average 93 stars, based on 1 article reviews
unbounded vegf165 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
vegf 165 (unbound to bevacizumab)  (R&D Systems)
90
R&D Systems vegf 165 (unbound to bevacizumab)
Patient and study characteristics
Vegf 165 (Unbound To Bevacizumab), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf 165 (unbound to bevacizumab)/product/R&D Systems
Average 90 stars, based on 1 article reviews
vegf 165 (unbound to bevacizumab) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Patient and study characteristics

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Patient and study characteristics

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques:

In vitro VEGF 165 concentrations after addition of bevacizumab

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: In vitro VEGF 165 concentrations after addition of bevacizumab

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: In Vitro

Population parameter estimates from the PK model (bevacizumab analyzed alone) and TMDD model (bevacizumab and VEGF 165 analyzed simultaneously)

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Population parameter estimates from the PK model (bevacizumab analyzed alone) and TMDD model (bevacizumab and VEGF 165 analyzed simultaneously)

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques:

Structure of the binding model for bevacizumab–VEGF 165 interaction. The approximation CL RC = CL was used for purposes of model fitting

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Structure of the binding model for bevacizumab–VEGF 165 interaction. The approximation CL RC = CL was used for purposes of model fitting

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Binding Assay

Prediction-corrected visual predictive checks of the binding model based on 1000 simulations (panel a total bevacizumab, panel b free VEGF 165 ). Median ( solid line ), 10th and 90th percentiles ( dashed lines ) of the observed data ( circles ) are compared to the 95 % confidence intervals ( shaded areas ) for the median, 10th and 90th percentiles of the simulated data

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Prediction-corrected visual predictive checks of the binding model based on 1000 simulations (panel a total bevacizumab, panel b free VEGF 165 ). Median ( solid line ), 10th and 90th percentiles ( dashed lines ) of the observed data ( circles ) are compared to the 95 % confidence intervals ( shaded areas ) for the median, 10th and 90th percentiles of the simulated data

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Binding Assay

Model-predicted concentrations of total bevacizumab, total and free VEGF 165 for a typical patient of 70 kg. Panels a , b show the total bevacizumab and free VEGF 165 concentration profiles at doses of 5 and 7.5 mg/kg, respectively. Panel c depicts the total VEGF 165 profiles over time for the two dosing regimens

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Model-predicted concentrations of total bevacizumab, total and free VEGF 165 for a typical patient of 70 kg. Panels a , b show the total bevacizumab and free VEGF 165 concentration profiles at doses of 5 and 7.5 mg/kg, respectively. Panel c depicts the total VEGF 165 profiles over time for the two dosing regimens

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Concentration Assay